Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral PARP1 inhibitor that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [1].
|
|
References |
1. Cai SX, Tian YE, Dong H, Xu Q, Wu L, Liu L, Jiang Y, Bao , Wang G, Yin F et al.. (2012)
1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof. Patent number: WO2012130166A1. Assignee: Impact Therapeutics, Inc.. Priority date: 01/04/2011. Publication date: 04/10/2012. |